Viability, Differentiation Capacity, and Detectability of Super-paramagnetic Iron Oxide-labeled Muscle Precursor Cells for Magnetic-resonance Imaging
Overview
Biotechnology
Authors
Affiliations
Cell therapies are a promising approach for the treatment of a variety of human conditions including stress urinary incontinence, but their success greatly depends on the biodistribution, migration, survival, and differentiation of the transplanted cells. Noninvasive in vivo cell tracking therefore presents an important aspect for translation of such a procedure into the clinics. Upon labeling with superparamagnetic iron oxide (SPIO) nanoparticles, cells can be tracked by magnetic resonance imaging (MRI), but possible adverse effect of the labeling have to be considered when labeling stem cells with SPIOs. In this study, human muscle precursor cells (hMPC) were labeled with increasing concentrations of SPIO nanoparticles (100-1600 μg/mL) and cell viability and differentiation capacity upon labeling was assessed in vitro. While a linear dependence between cell viability and nanoparticle concentration could be observed, differentiation capacity was not affected by the presence of SPIOs. Using a nude mouse model, a concentration (400 μg/mL) could be defined that allows reliable detection of hMPCs by MRI but does not influence myogenic in vivo differentiation to mature and functional muscle tissue. This suggests that such an approach can be safely used in a clinical setting to track muscle regeneration in patients undergoing cell therapy without negative effects on the functionality of the bioengineered muscle.
Diagnostic and therapeutic roles of iron oxide nanoparticles in biomedicine.
Lu C, Hsiao J Tzu Chi Med J. 2023; 35(1):11-17.
PMID: 36866343 PMC: 9972926. DOI: 10.4103/tcmj.tcmj_65_22.
Adult stem cell sources for skeletal and smooth muscle tissue engineering.
Salemi S, Prange J, Baumgartner V, Mohr-Haralampieva D, Eberli D Stem Cell Res Ther. 2022; 13(1):156.
PMID: 35410452 PMC: 8996587. DOI: 10.1186/s13287-022-02835-x.
Biodistribution studies for cell therapy products: Current status and issues.
Kamiyama Y, Naritomi Y, Moriya Y, Yamamoto S, Kitahashi T, Maekawa T Regen Ther. 2021; 18:202-216.
PMID: 34307798 PMC: 8282960. DOI: 10.1016/j.reth.2021.06.005.
Schmid F, Gascho D, Zoelch N, Prange J, Colacicco G, Eberli D BMC Urol. 2020; 20(1):167.
PMID: 33097063 PMC: 7583166. DOI: 10.1186/s12894-020-00719-x.
Zhou S, Yin T, Zou Q, Zhang K, Gao G, Shapter J Sci Rep. 2017; 7:42793.
PMID: 28220818 PMC: 5318892. DOI: 10.1038/srep42793.